You are not logged in
Login
Create Account
Meetings
Help
Contact Us
Visit our Twitter
Visit our LinkedIn
Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch Post-Meeting Survey
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
Name
Email Address
Which patients with HCC are eligible for 1st line IO?
Child Pugh class C patients
Patients with active and uncontrolled auto-immune disease
HCC recurrent patients after liver transplantation
Patients with a bleeding history
All of the above
None of the above
When do you switch to 2nd line treatment following IO 1st line?
Upon disease progression as per mRECIST criteria
As soon as immune-related adverse events occur
Both
Neither of these scenarios
What is your 2nd line treatment of choice, following IO 1st line?
Sorafenib
Lenvatinib
Regorafenib
Cabozantinib
Atezolizumab + Bevacizumab (if not used previously)
Durvalumab + Tremelimumab (if not used previously)
On a scale of 1 to 5, how do you rate your knowledge (with 5 as extremely knowledgeable) on the outcomes data of IO 1st line in patients with advanced HCC?
1
2
3
4
5
On a scale of 1 to 5, how familiar are you (with 5 as extremely familiar) in determining the right time to switch from IO 1st line to 2nd line treatment?
1
2
3
4
5
On a scale of 1 to 5, how confident (with 5 as extremely confident) are you in understanding the data supporting 2nd line treatment options for patients with advanced HCC, to enable optimal sequencing?
1
2
3
4
5
On a scale of 1 to 5, how valuable (with 5 as extremely valuable) did you find this Experts Knowledge Share on ‘Treatment options for HCC patients who are not eligible for or progressed on IO. Clinical considerations and when to switch’
1
2
3
4
5
On a scale of 1 to 5, how strongly do you agree that your knowledge of the Treatment options for HCC patients who are not eligible or progressed on IO has improved as a result of participating in this programme (with 5 as very strongly agree)
1
2
3
4
5
Are you planning to change your clinical practice based upon you participation in this Experts Knowledge Share?
Yes
Possibly
No, the content confirms my current practice
No, I am unable to change my current practice
What will be the main change you will make in your clinical practice after attending this Experts Knowledge Share meeting?
On a scale of 1-5 (with 5 as very balanced and unbiased), to what extent do you feel this Experts Knowledge Share was balanced and unbiased?
1
2
3
4
5
Do you have any other comments or feedback?
Send Feedback
Honorarium
We are pleased to offer an honorarium payment for participation in this interactive meeting
Honorarium Form
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Bodenackerstrasse 17
4103 Bottmingen
Switzerland
Products
Webinars
Meetings
On Demand
SUPPORT
HELP
CONTACT US
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved
Cookies
Privacy Policy
map-marker
sign-in
user-plus
credit-card-alt
linkedin
facebook
pinterest
youtube
rss
twitter
instagram
facebook-blank
rss-blank
linkedin-blank
pinterest
youtube
twitter
instagram
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept
View Cookie Policy
